Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical

Status Recruiting

Clinical Trial Summary

The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.

Clinical Trial Description

Electrical storm (ES), defined as three or more sustained or treated ventricular arrhythmias in a 24-hour period, is a life-threatening condition that is associated with significant short- and long-term mortality. Autonomic dysfunction from increased sympathetic tone and the catecholamine surge from defibrillator shocks can precipitate recurrent ventricular arrhythmias and exacerbate ES. Although the mainstay of treatment are anti-arrhythmic drugs, sedative agents and procedures are commonly used to decrease sympathetic tone. These therapies have been studied in refractory ES but the benefit of early sedation remains unclear. Alpha-2 agonism with dexmedetomidine can provide conscious sedation without the need for mechanical ventilation. Dexmedetomidine has been found to reduce ventricular arrhythmia events in non-ES patients in the intensive care unit and in the peri-operative period. Its antiarrhythmic properties are thought to be due to catecholamine suppression, prolonging electrical refractory periods, and increasing vagal tone. Its rapid onset and favorable safety profile render alpha-2 agonism with dexmedetomidine a potentially valuable therapy for patients with ES. This study is a multi-centre, double-blinded, placebo-controlled, randomized trial that will evaluate the effectiveness of dexmedetomidine in the acute treatment of ES. Consecutive patients admitted to an intensive care unit will be randomized to receive dexmedetomidine or placebo at the time of presentation. The study drug will be titrated to a maintenance dose and continued for 48 hours before being weaned. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06281977
Study type	Interventional
Source	Ottawa Heart Institute Research Corporation
Contact	F. Daniel Ramirez, MD MSc
Phone	613-696-7402
Email	dramirez@ottawaheart.ca
Status	Recruiting
Phase	Phase 3
Start date	May 8, 2024
Completion date	August 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03453645` - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed	`NCT05970120` - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter	N/A
Completed	`NCT05791032` - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study	N/A
Completed	`NCT04011631` - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System.	N/A
Recruiting	`NCT03536052` - Ablation at Virtual-hEart pRedicted Targets for VT	N/A
Not yet recruiting	`NCT06063811` - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation	`NCT02962076` - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia	Early Phase 1
Not yet recruiting	`NCT02784912` - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation	N/A
Completed	`NCT01791543` - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia	N/A
Terminated	`NCT02891863` - Low Energy Therapy to Convert Ventricular Tachycardias	Phase 0
Terminated	`NCT01546207` - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia	N/A
Completed	`NCT01294267` - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation	N/A
Terminated	`NCT00383799` - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia	Phase 4
Completed	`NCT04884100` - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening	N/A
Completed	`NCT04642963` - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia	N/A
Recruiting	`NCT05377216` - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation	Early Phase 1
Not yet recruiting	`NCT04990089` - VIVO European Observational Registry
Completed	`NCT04065893` - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting	`NCT03631303` - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting	`NCT03611465` - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm — SEDATE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms